

Index

- ABO blood group 105–7
 - ABO-hemolytic disease of the fetus and newborn 107–8
 - clinical presentation 107
 - diagnosis 108
 - fetus management 113–14
 - prevalence 107
 - incompatibility protective effect against Rh immunization 110
- abortion, disseminated intravascular coagulation and 16
- abruptio placenta *see* placental abruption
- acidosis, disseminated intravascular coagulation and 18
- acquired hemophilia 94–6
 - characteristics 94–5
 - laboratory findings 95
 - treatment 95–6
- acquired von Willebrand syndrome (aVWS) 87, 578
 - see also* von Willebrand disease (VWD)
- activated partial thromboplastin time (aPTT) 81–2
 - in disseminated intravascular coagulation 26
 - lupus anticoagulants and 152, 169–70
- activated protein C (APC) 201–2
 - resistance 207–8
 - acquired 210
 - factor V Cambridge mutation 136–7
 - factor V HR2 haplotype 137
 - factor V Leiden mutation 134–5, 207–8
 - management 137
- activated prothrombin complex concentrates 96
- acute chest syndrome 450–1
- acute fatty liver of pregnancy (AFLP) 497
- acute heparin reaction 129
- ADAMTS13 497–8
- adult respiratory distress syndrome (ARDS) 407
- adult shock-lung syndrome 24–5
- aldosterone synthesis, heparin therapy affect 133
- alopecia, heparin therapy and 134
- alpha-2-antiplasmin deficiency 385
- amniocentesis 475–6, 477
- amniotic fluid embolism (AFE) 3–13, 395, 420
 - diagnosis 12
 - etiology 4–7
 - risk factors 6
 - incidence 5–6
 - management 12–13, 14–15
 - mortality 5–6, 7
 - pathophysiology 8–9
 - hemostasis pathophysiology 10
 - pulmonary pathophysiology 9–10
- amniotic webs 258
- anacrod 563
- anaphylaxis, heparin-associated 129
- anemia 269, 271, 278, 282, 543
 - acute episodes in sickle cell disease 451–2
 - megaloblastic 290–1
 - microcytic 282
 - significance of 269
 - see also* hemolytic disease of the fetus and newborn; iron deficiency; sickle cell disease
- anencephaly 292
- annexin-V, antiphospholipid antibody effects 59
- antenatal diagnosis *see* prenatal diagnosis
- antepartum hemorrhage 365–6, 367
- anti-D IgG therapy 494
- anti-Xa drugs 355–6
- antibiotics, post partum hemorrhage management 405–6
- anticardiolipin antibodies (ACLA) 156–64, 208–9
 - assay 156
 - autoimmune collagen disease 161–2

590 Index

- anticardiolipin antibodies (ACLA) (cont.)
 - cardiac disease and 158–9
 - cutaneous manifestations 159–60
 - detection of 169
 - lupus anticoagulant correlation 153, 156–7, 171
 - miscellaneous disorders 163–4
 - neurologic syndromes 160–1
 - obstetric syndromes 162–3
 - prevalence 168–9
 - thrombosis and 149, 156, 157–8, 160–1
 - mechanism 157–8
 - subclassification 154, 164–6
 - see also* antiphospholipid syndromes (APLS)
- anticoagulant therapy
 - disseminated intravascular coagulation
 - management 421–3
 - during pregnancy 350–1
 - guidelines 351–5
 - management of at risk pregnant patients 352
 - patients already receiving anticoagulation 353
 - patients at risk of pregnancy loss 353–5
 - prophylaxis with mechanical heart valves 353
 - venous thrombosis treatment during pregnancy 352
 - newer anticoagulant drugs 355–7
 - see also* antithrombotic therapy; heparin treatment; warfarin treatment
- antifibrinolytic therapy
 - disseminated intravascular coagulation 40
 - menorrhagia with von Willebrand disease 577–8
 - post partum hemorrhage 403–4
- antiphospholipid syndromes (APLS) 148–50, 165, 174, 208–9, 344
 - cerebrovascular thrombosis 175–6
 - classification 154, 164–6, 209
 - clinical presentations 166–8
 - coronary artery thrombosis 175
 - drugs associated with 168
 - laboratory diagnosis 169–72
 - detection of antiphospholipid antibody subtypes 171–2
 - late pregnancy complications 209
 - management 165–6, 209, 351, 353, 354
 - prevalence 168–9
 - recurrent miscarriage association 58–9, 64, 162–3, 208–9
 - mechanisms 59, 61
 - monitoring 58
 - treatment review 68–9
 - types of antiphospholipid antibodies 172
 - see also* anticardiolipin antibodies (ACLA); lupus anticoagulants (LA)
- antiplatelet medications
 - bleeding disorders and 82–3
 - heparin-induced thrombocytopenia
 - management 565–6
 - see also* aspirin (ASA) treatment
- antithrombin (AT)
 - deficiency 140–2, 206–7
 - management 141–2
 - monitoring 142
 - determination, disseminated intravascular coagulation therapy 30–1
 - treatment 141–2
- amniotic fluid embolism 13
- disseminated intravascular coagulation 38
- disseminated intravascular coagulation, low-grade DIC 41
- antithrombotic therapy
 - disseminated intravascular coagulation 37–8
 - guidelines 351–5
 - management of at risk pregnant patients 352
 - patients at risk for pregnancy loss 353–5
 - pregnant patients already receiving anticoagulation 353
 - prophylaxis with mechanical heart valves 353
 - venous thrombosis treatment in pregnancy 352
 - newer antithrombotic drugs 355–7
- thrombophilia 122–3, 124–34
 - bridging therapy 126–7
 - factor V Cambridge mutation 137
 - factor V Leiden mutation 135–6
 - heparin side effects 128–34
 - treatment monitoring 127
 - see also* heparin treatment; warfarin treatment
- Argatroban 565, 566
- arterial ligation 414–15
 - internal iliac (hypogastric) artery 415
 - uterine artery 414
- aspirin (ASA) treatment
 - platelet inhibition 82
 - recurrent miscarriage management 63–4, 162–3, 258, 351
 - outcomes 67
 - treatment review 68–9
 - thrombophilia 123, 137
 - factor V Leiden mutation 136
- atherosis, acute 254

591 Index

- autoimmune collagen disease, anticardiolipins and 161–2
- autosomal dominant inheritance 472–3
- autosomal recessive inheritance 471–2
- autotransfusion, post partum hemorrhage management 400
- B-Lynch suture 416–17
 - modified 417
- bacterial infection, disseminated intravascular coagulation and 17–18
- bed rest, as risk factor for DVT 205–6
- Bernard-Soulier syndrome (BSS) 91–2
- Bethesda assay 95
- bilirubin, in hemolytic disease of the fetus and newborn 105, 114
 - exchange transfusion 114
- Bivalirudin 565
- bleeding disorders 75
 - antepartum hemorrhagic diatheses 373–7
 - management 376
 - screening 372, 373
 - evaluation 79–80
 - laboratory evaluation 80–2
 - genetic counseling 96
 - post partum hemorrhage prevention 373–7
 - see also* post partum hemorrhage
 - prenatal testing 96
 - primary hemostatic defect 82–92
 - antiplatelet medications and 82–3
 - recurrent miscarriage associations 55–6, 57, 63
 - secondary hemostatic dysfunction 92–6
 - uremic bleeding 91
 - see also* hemorrhage; specific disorders
- blood coagulation protein/platelet defects, in recurrent miscarriage 55–8
- blood component therapy 528, 533
 - administration 540–1
 - blood collection 528–9
 - cryoprecipitate (CRYO) 538–40, 546
 - indications 539–40
 - preparation and storage 538–9
 - disseminated intravascular coagulation 39–40
 - fresh frozen plasma (FFP) 537–8, 546
 - indications 537–8
 - preparation and storage 537
 - modifications to whole blood and components 540
 - irradiation 540
 - leukocyte reduction 540
 - washing 540
 - new pharmacological agents 541–3
 - erythropoietin (EPO) 541–2
 - recombinant factor VIIa (Novoseven) 542
 - red blood cell substitutes 541
 - packed red blood cells (PRBCs) 534–5
 - indications 534–5
 - preparation and storage 534
 - platelets 535, 546
 - considerations 536–7
 - indications 536
 - intrauterine platelet transfusion (IUPIT) 514–15
 - random donor platelets (RDPs) 535
 - single donor platelets (SDPs) 535–7
 - transfusion 401–2, 495, 499
 - post partum hemorrhage 398–402
 - whole blood 531–4
 - indications 534
 - preparation and storage 531
 - use with massive hemorrhage 545–6
 - see also* blood transfusion
- blood donation 528–9
- blood pressure, post partum hemorrhage monitoring 406
- blood transfusion 540–1
 - autotransfusion, post partum hemorrhage management 400
 - disseminated intravascular coagulation (DIC) 547
 - exchange transfusion, hemolytic disease of the fetus and newborn 114
 - management 544
 - guidelines 544
 - massive transfusion 538, 544–6
 - complications 546
 - CRYO 546
 - definition 544
 - fresh frozen plasma 546
 - laboratory investigation 544–5
 - platelets 546
 - treatment 545
 - uncrossmatched, emergency release red blood cells 545
 - whole blood 545–6
 - pretransfusion compatibility testing 530–1
 - risks of transfusion therapy 529–30
 - infectious risks 529–30
 - non-infectious risks 530
 - sickle cell disease management during pregnancy 449–50, 547–8
 - at delivery 450

592 Index

- blood transfusion (cont.)
 - red blood cell exchange (RBCx) 547–8
 - see also* blood component therapy; intra-uterine transfusion
- bone density, heparin therapy effects 129–32, 350
- breast cancer
 - folate intake relationship 295
 - venous thrombosis risks 310
 - during chemotherapy 320–7
 - prophylaxis 326–7
 - see also* malignancy
- cesarean section, as risk factor for DVT 202–3
- cancer *see* malignancy; *specific types of cancer*
- cardiac disease, antidiolipins and 158–9
 - myocardial infarction 158–9
 - valvular disease 159
- central venous catheters, venous thrombosis risks 327–31
 - prophylaxis 328–31, 333
- central venous pressure monitoring 406–7
- cerebrovascular events
 - antiphospholipid antibodies and 160–1, 175–6
 - with sickle cell disease 451
- chemotherapy, venous thrombosis risks 320–7
 - prophylaxis 326–7, 332–3
- chorangiomas 258–9
- chorionic villus sampling (CVS) 476, 477
- Christmas disease 382–3
- chronic venous insufficiency (CVI) 212
- clotidogrel
 - antiphospholipid syndrome management 165–6
 - platelet inhibition 83
- coagulation factor 3–16, 77–9, 373
 - defects
 - menorrhagia and 571–2, 573, 574–81
 - recurrent miscarriage syndrome and 55–8
 - surgical considerations 582–3
 - see also specific defects*
 - inhibitors of 94
 - acquired hemophilia 94–6
 - see also* disseminated intravascular coagulation (DIC)
- coagulation factor
 - assays, disseminated intravascular coagulation 26–7
 - deficiencies 93–4
- cobalamin *see* vitamin B₁₂
- colon cancer
 - folate status relationship 295
 - see also* malignancy
- complement activation, disseminated intravascular coagulation 21
- compression ultrasound (CUS) 213
- contraception
 - oral, menorrhagia treatment with von Willebrand disease 577
 - sickle cell disease and 453
- coronary artery thrombosis 175
- coumadin 563
- counseling *see* genetic counseling
- Creutzfeldt–Jakob disease (CJD) 529–30
- cryoprecipitate (CRYO) 538–40
 - dysfibrinogenemia management 377
 - in massive transfusion 546
 - indications 539–40
 - post partum hemorrhage management 402
 - preparation and storage 538–9
 - use in surgery 583
 - von Willebrand disease management 89, 388
- D-Dimer assay
 - disseminated intravascular coagulation 27–8
 - DVT diagnosis 213–14
- Dallas Thrombosis Hemostasis Clinical Center, recurrent miscarriage experience 61–9
 - flow protocol 61
 - management 63–6
 - outcomes 67
 - patient characteristics 62–3
 - treatment review 68–9
- dalteparin *see* heparin treatment
- danaparoid (Organon) 564
- danazol, menorrhagia treatment 581
- DDAVP (desmopressin)
 - factor VIII: C defect management 380–1
 - platelet aggregation disorder management 579
 - during surgery 583
 - von Willebrand disease management 89–90, 388
 - preoperative treatment 582–3
 - with menorrhagia 576–7
- deep vein thrombosis (DVT)
 - diagnosis in pregnancy 213–14
 - incidence in pregnancy 200
 - long-term outcome 212
 - management in pregnancy 214–16
 - at time of delivery 215–16
 - mortality 201
 - pathogenesis in pregnancy 201–2

- prophylaxis in pregnancy 210–13
 - heparin dosage 211, 212, 215
 - with prosthetic heart valves 212
- risk factors 202–6, 210–11
 - age at delivery 205
 - bed rest and obesity 205–6
 - cesarean section 202–3
 - previous history 204, 210
 - risk of in pregnancy 122, 211
- thrombophilia and 206–10
 - antiphospholipid syndrome 208–9
 - inherited thrombophilia 134–6, 206–8
 - see also* thrombophilia in pregnancy; thrombosis; venous thromboembolism (VTE)
- Dego's disease 159–60
- delivery
 - deep vein thrombosis management 215–16
 - post partum hemorrhage prevention 389–92
 - with sickle cell disease 450
- desmopressin *see* DDAVP
- dilute Russell's viper venom time (dRVVT)
 - 152–3, 170
 - anticoagulant therapy effects 170–1
- direct antiglobulin test (DAT) 108–10
- disseminated intravascular coagulation (DIC) 1–3, 418–23, 546–7
 - associated disorders 2, 3, 4, 5, 421
 - clinical diagnosis 22–3, 33, 422
 - low-grade DIC 23
 - definition 2
 - etiology 3–18, 419–20, 546–7
 - disorders not specific to pregnancy or gynecology 5, 17–18
 - disorders specific to gynecology 16–17
 - disorders specific to pregnancy and obstetrics 3–16
 - historical perspectives 3
 - laboratory diagnosis 22, 25–35
 - global coagulation tests 25–9
 - molecular markers 29–35
 - management 35–41, 421–3, 547
 - anticoagulants 421–3
 - fresh frozen plasma 538
 - fulminant DIC 35–40
 - low-grade DIC 40–1
 - removal of triggering pathophysiology 36–7
 - transfusion therapy 547
 - with post partum hemorrhage 402, 403–4
 - morphological findings 23–5
 - pathophysiological events 19–22
 - prevention 420–1
- dysfibrinogenemia 139, 377
 - treatment 377, 539
- eclampsia 13–15
 - disseminated intravascular coagulation and 13–15
 - with sickle cell disease 453
 - see also* preeclampsia
- embolization, post partum hemorrhage management 408–10
- enaxta 355
- endometrial ablation, menorrhagia treatment 582–3
- endotoxin, disseminated intravascular coagulation and 17–18
- enoxaparin (Lovenox), safety issues in pregnancy 65–7, 125, 127, 556–7
 - adverse effects 67
 - non-teratogenic effects 66–7
 - teratogenic effects 66
 - see also* heparin treatment
- enzyme-linked immunosorbent assay (ELISA) 509
- eosinophilia, heparin therapy and 133
- epsilon aminocaproic acid (AECA)
 - disseminated intravascular coagulation therapy 40
 - menorrhagia treatment with von Willebrand disease 578
 - post partum hemorrhage management 403–4
- ergotamine 391
- erythroblastosis fetalis 105
- erythropoietin (EPO) 541–2
- Factor Eight Inhibitor Bypass Activity (FEIBA) 96
- factor II defects 377–8
 - management 378–9
- factor V defects 378–9
 - Cambridge mutation 136–7
 - Hong Kong mutations 137
 - HR2 haplotype 137
 - Leiden mutation 134–6, 207–8
 - factor V HR2 haplotype effect 137
 - management 135–6
 - recurrent miscarriage association 60
 - menorrhagia and 580
- factor VII defects 379–80
 - management 379–80
 - menorrhagia and 580

594 **Index**

- factor VIIa
 - post partum hemorrhage management 402
 - recombinant (Novoseven) 542
- factor VIII
 - deficiency (hemophilia A) 380–2
 - inheritance patterns 478–80
 - management 380–2
 - von Willebrand disease comparison 388
 - elevation 210
 - inhibition *see* acquired hemophilia
 - replacement therapy during surgery 583
- factor IX
 - deficiency (hemophilia B) 382–3
 - inheritance patterns 478–80
 - management 382–3
 - elevation 210
- factor X
 - activation, in disseminated intravascular coagulation 10, 17
 - deficiency 383–4
 - management 383–4
- factor XI
 - deficiency 93, 384
 - management 384
 - menorrhagia and 580
 - elevation 210
- factor XII deficiency (Hageman trait) 139
- factor XIII deficiency 385–6, 539
 - management 386, 539
- ferritin measurement 279–80
- fetal hydrops *see* hydrops fetalis
- fetal scalp sampling 514
- fetal thrombotic vasculopathy 260
- fetal wastage syndrome *see* recurrent miscarriage syndrome
- fibrin
 - in disseminated intravascular coagulation 19–20, 21
 - assays 27
 - placental, obstructive lesions and 254–5
 - intimal fibrin cushions 260
 - maternal floor infarction 255
- fibrinogen defects 139, 377, 539
 - treatment 377, 539
- fibrin(ogen) degradation products (FDPs), in
 - disseminated intravascular coagulation 19–20
 - assays 27–9
- fibrinolytic system defects
 - disseminated intravascular coagulation 31–2, 40
 - antifibrinolytic therapy 40
 - assays 31–2
 - thrombosis and 145–6
- fibrinopeptide A (FPA) assay 29–30, 31
- fibromuscular sclerosis 260
- Fletcher factor deficiency 384
- FM-test, disseminated intravascular coagulation 27
- folate 284–5
 - cancer and 294–5
 - breast cancer 295
 - colon cancer 295
 - deficiency
 - diagnosis 287–9
 - hematological sequelae 290–1
 - neural tube defects 292–3
 - treatment 295–6
 - food fortification 289–90, 292–3
 - homocysteine interrelationship 285–6
 - in sickle cell disease 449
 - preeclampsia and 294
 - requirements during pregnancy 289–90
- Foley catheter 412
- fractures, heparin therapy association 129–32, 350
- fresh frozen plasma (FFP) 537–8, 546
 - indications 537–8
 - post partum hemorrhage management 400–1
 - preparation and storage 537
- gelfoam 409
- genetic counseling 469, 470–4
 - β thalassemia 460
 - bleeding disorders 96
 - hemophilia 478–80
 - von Willebrand disease 484–5
 - components of 470–4
 - choosing course of action 473–4
 - making best possible adjustment 474
 - understanding alternatives for dealing with risk 473
 - understanding heredity and risk of recurrence 471–3
 - understanding medical facts 471
- Hb H disease 457–8
- hemoglobinopathies 480–4
 - sickle cell disease 453
- hydrops fetalis 457–8
- thrombophilia 477–8
 - see also* inheritance patterns
- genetic counselors 470
- Glanzmann’s thrombasthenia (GT) 92, 579

- gonadotropin releasing hormone (GnRH),
menorrhagia treatment 581
 - Hageman trait 139
 - Helicobacter pylori* infection, thrombocytopenia
and 495
 - HELLP syndrome 14–16, 420, 496
 - disseminated intravascular coagulation and 15–16
 - management 496
 - hemangiomas, umbilical 258–9
 - hemoglobin 442
 - function 442
 - Hb Bart’s hydrops fetalis 456–9, 483–4
 - fetal and maternal complications 457
 - gene deletions 457
 - genetic counseling 457–8
 - Hb H disease 456, 458, 483–4
 - genetic counseling 457–8
 - pregnancy 456
 - prenatal diagnosis 458–9
 - levels 278–9
 - monitoring following post partum
hemorrhage 406
 - mutations 442–3, 454–5
 - inheritance patterns 480–4
 - see also* anemia; iron deficiency; sickle cell disease;
thalassemias
 - hemolytic disease of the fetus and newborn (HDFN)
 - alloimmunized female management during
pregnancy 112
 - erythrocyte antigens implicated 105–11, 486–7
 - ABO blood group system 105–8
 - anti-Kell 110, 486–7
 - diagnosis 110
 - Rh (D) 108–10
 - see also* ABO blood group; Rh
isoimmunization
 - fetus management 112–14
 - amniocentesis and Liley curves 112–13
 - intra-uterine transfusion (IUT) 113–14
 - neonate management 114
 - pathophysiology 103–5
 - effects on fetus 105
 - events leading to disease 103–5
 - hydrops fetalis 105
 - prevention in Rh(D) negative, unsensitized
female 111–12
 - protective effect of ABO-incompatibility 110
- hemolytic uremic syndrome (HUS) 499–500
- hemophilia, acquired *see* acquired hemophilia
- hemophilia A (factor VIII deficiency) 380–2
 - inheritance patterns 478–80
 - management 380–2
 - von Willebrand disease comparison 388
- hemophilia B (factor IX deficiency) 382–3
 - inheritance patterns 478–80
 - management 382–3
- hemophilia carriers, menorrhagia and 580
- hemorrhage 543–4
 - antepartum hemorrhage 365–6, 367
 - antepartum hemorrhagic diatheses 373–7
 - management 376
 - screening 372, 373
 - gastrointestinal, iron deficiency and 274–5, 282
 - heparin therapy side effect 128–9
 - in disseminated intravascular coagulation 2, 20,
21, 22
 - management 39–40
 - see also* disseminated intravascular coagulation
 - intracranial (ICH), with neonatal alloimmune
thrombocytopenia 513
 - physiologic parturition hemorrhage 362
 - placental 250
 - disturbances of fetal vascular integrity 260–2
 - disturbances of maternal vascular integrity
255–7
 - iatrogenic 261–2
 - see also* placenta
 - see also* bleeding disorders; post partum
hemorrhage (PPH)
- hemorrhagic endovascularitis 260
- hemorrhagic shock 393–6
 - clinical manifestations 395
 - consequences 365
 - resuscitation 396–8
 - severity indices 394
 - see also* post partum hemorrhage
- hemostatic sutures 415–18
 - B-Lynch suture 416–17
 - modified 417
 - multiple square suturing 417–18
- hemostatic system 75–7
 - antepartum hemorrhagic
diatheses 373–7
 - management 376
 - screening 372, 373
- clotting system during pregnancy 79
- hemostasis mechanism with menstruation 571
- hemostatic changes during pregnancy 202,
342–3, 371

596 Index

- hemostatic system (cont.)
 - primary hemostasis 75–7
 - laboratory evaluation 80–1
 - primary hemostatic defect 82–92
 - secondary hemostasis 76–7
 - laboratory evaluation 81–2
- heparin cofactor II (HC-II) deficiency 142
- heparin-induced thrombocytopenia (HIT) 354, 556, 557–66
 - clinical testing 562–3
 - functional tests 562
 - quantitative tests 562–3
 - differential diagnosis 561–2
 - frequency 559
 - HIT-associated thrombosis 560–1
 - management 561, 563–6
 - alternative anticoagulants 563
 - antiplatelet agents 565–6
 - Argatroban 565, 566
 - coumadin 563
 - danaparoid (Organon) 564
 - direct thrombin inhibitors 564, 566
 - hirudin 564–5, 566
 - pathophysiology 559–60
 - risk factors 560
 - type I 557–8
 - type II 558–9
- heparin treatment 346, 350–1, 556–7
 - amniotic fluid embolism 13
 - disseminated intravascular coagulation 37–8
 - low-grade DIC 41
 - DVT management 214–16
 - at time of delivery 215–16
 - DVT prophylaxis 210, 211
 - dosage 211, 212, 215
 - with prosthetic heart valves 212
 - low molecular weight heparin (LMWH)
 - properties 344–50
 - use in pregnancy 350–1
 - prophylaxis in cancer patients
 - during chemotherapy 326, 327
 - during surgery 315–19, 331–2
 - with central venous catheters 331, 333
 - recurrent miscarriage management 63–6, 162–3, 351
 - outcomes 67
 - treatment review 68–9
 - safety issues in pregnancy 65–7, 125, 127, 212–13, 556–7
 - side effects 128–34, 213, 556
 - acute heparin reaction 129
 - alopecia 134
 - altered liver function 133
 - bleeding 128–9
 - eosinophilia 133
 - metabolic abnormalities 133
 - osteoporosis 129–32, 350
 - skin reactions 132–3
 - see also* heparin-induced thrombocytopenia (HIT)
 - thrombophilia 123, 124–34, 137
 - antiphospholipid syndromes 165–6, 209, 351, 353, 354
 - bridging therapy 126–7
 - factor V Leiden mutation 135–6
 - lupus anticoagulant thrombosis syndrome 155–6
 - protein C deficiency 142–4
 - protein S deficiency 144–5
 - treatment monitoring 127
 - venous thrombosis management guidelines in
 - pregnancy 352
 - at risk patients 352
 - patients already receiving
 - anticoagulation 353
 - patients at risk for pregnancy loss 353–5
 - patients with mechanical heart valves 353
 - see also* antithrombotic therapy
- hepatosplenomegaly, hemolytic disease of the fetus and newborn 105
- hirudin 564–5, 566
- homocysteine 284–6
 - folate and vitamin B₁₂ interrelationship 285–6
 - use in folate and vitamin B₁₂ deficiency diagnosis 288
- homocyst(e)inemia 139–40
 - management 140
- hyperhomocysteinemia 286–7
 - intrauterine growth retardation and 294
 - miscarriage and 293
 - preeclampsia and 294
 - treatment 296–7
- homocystinuria 286
- hormone releasing intrauterine device, menorrhagia treatment 581
- human leukocyte antigens (HLA) 516–17
 - anti-HLA antibodies 517

597 Index

- human platelet antigen (HPA) polymorphisms 507–8
 - HPA-1 system 508
 - HPA-3 system 508
 - HPA-5 system 508
- Humate-P 88–9, 90–1, 388
- hyaline microthrombi, disseminated intravascular coagulation 24–5
- hydrops fetalis 105, 112
 - genetic counseling 457–8
 - Hb Bart’s hydrops fetalis 456–9, 483–4
 - fetal and maternal complications 457
 - gene deletions 457
- hydroxyurea, sickle cell disease management 448
- hyperbilirubinemia, in hemolytic disease of the fetus and newborn 105, 114
 - exchange transfusion 114
- hyperhomocysteinemia 286–7
 - intrauterine growth retardation and 294
 - miscarriage and 293
 - preeclampsia and 294
 - treatment 296–7
 - see also* homocysteine
- hyperkalemia, heparin therapy and 133
- hypertrophic decidual vasculopathy 254
- hypoaldosteronism, heparin therapy and 133
- hypogastric artery ligation 415
- hypovolemic shock *see* hemorrhagic shock
- hysterectomy
 - menorrhagia management 581–2
 - post partum hemorrhage management 418
- immune thrombocytopenic purpura (ITP) 492–5, 517–18
 - clinical presentation 492, 517
 - diagnosis 492
 - differential diagnosis 518
 - laboratory values 518
 - fetal assessment 493
 - history 518
 - management 492–5, 518
 - neonatal 519
 - assessment 493
 - degree of thrombocytopenia 519
 - incidence 519
 - management 493, 519
 - pathophysiology 517
- immunosuppressive therapy
 - acquired hemophilia 96
 - lupus anticoagulant thrombosis syndrome 154
 - impedence plethysmography (IPG)
- implantation 253
 - superficial implantation 253
 - placental lesions 254
- infarction, placental 255
 - maternal floor infarction 255
- inheritance patterns 470
 - autosomal dominant inheritance 472–3
 - autosomal recessive inheritance 471–2
 - genetic counseling 471–3
 - hemoglobinopathies 480–4
 - sickle cell disease 481
 - hemophilia 478–80, 489
 - Rh blood group system 486
 - thrombophilia 477–8
 - von Willebrand disease 484–5
 - X-linked inheritance 473
- interhemal membrane *see* placenta
- internal iliac artery ligation 415
- intrauterine growth retardation (IUGR)
 - homocysteine and 294
 - maternal underperfusion and 254
- intrauterine transfusion (IUT), fetal hemolytic disease management 113–14
 - indications 113
 - red blood cells 113–14
- intracranial hemorrhage (ICH), with neonatal alloimmune thrombocytopenia 513
- intravenous gamma globulin (IVIg) therapy, thrombocytopenia 494
 - fetal thrombocytopenia treatment 512
- iron deficiency 269, 270–84
 - causes 271, 274–5
 - clinical manifestations 276–7
 - development of 272
 - diagnosis 277–80
 - history and physical examination 277–8
 - laboratory studies 278–80
 - diagnostic evaluation 281–2
 - pregnancy and 271, 273
 - prevalence 270–1
 - screening 281
 - supplementation in sickle cell disease 449
 - treatment 282–4
 - see also* anemia
- iron homeostasis 271–5, 274
 - absorption from diet 272, 275–6
 - body iron distribution 272
 - during pregnancy 275–6
 - environmental influences 274–5

598 Index

- iron homeostasis (cont.)
 - iron loss 273–4
 - during pregnancy 273
- Ivalon® particles 409
- Jehovah’s Witnesses 542–3
- kaolin clotting time (KCT) 153, 170
- Kell antigen 110, 486–7
- kinin system activation, disseminated intravascular coagulation 21
- kininogen deficiency 385
- labor management, post partum hemorrhage
 - prevention 389–92
 - see also* delivery
- laparotomy, post partum hemorrhage treatment 414–18
 - arterial ligation 414–15
 - internal iliac (hypogastric) artery 415
 - uterine artery 414
 - hemostatic sutures 415–18
- Lepirudin 564–5
- LeVeen shunts 17
- Liley curves 112–13
- liver disease 537
- liver function, heparin therapy effects 133
- livido reticularis 159, 161
- Lovenox (enoxaparin), safety issues in pregnancy 65–7, 125, 127, 556–7
 - adverse reactions 67
 - non-teratogenic effects 66–7
 - teratogenic effects 66
 - see also* heparin treatment
- low molecular weight heparins (LMWHs) 344–50
 - clinical trials 349
 - dosages 347–8
 - heterogeneity 347–9
 - indications 348, 349
 - mechanism of action 347
 - preparation of 345–6
 - use in pregnancy 350–1
 - see also* heparin treatment
- lupus anticoagulants (LA) 150–6, 208–9
 - anticardiolipin antibody correlation 153, 156–7, 171
 - assays 152–3, 169–71
 - thrombosis and 149, 150–1
 - management 154–6
 - mechanisms 153
 - subclassification 154
 - see also* antiphospholipid syndromes (APLS)
- magnetic resonance venography
- malignancy 310–11
 - disseminated intravascular coagulation and 16–17
 - venous thrombosis prophylaxis 310–11
 - during chemotherapy 326–7, 332–3
 - during radiotherapy 320
 - during surgery 315–19, 331–2
 - recommendations 331–3
 - with central venous catheters 328–31, 333
 - venous thrombosis risks 310, 311–14
 - age and 312–13, 314–19
 - during cancer surgery 312–13, 314–19
 - during chemotherapy 320–7
 - during radiotherapy 319–20
 - influencing factors 311–14
 - with central venous catheters 327–31
 - see also specific types of cancer*
- menorrhagia 570
 - alternative treatments 581
 - coagulation defects and 571–2, 574–81
 - acquired von Willebrand syndrome 578
 - factor V deficiency 580
 - factor VII deficiency 580
 - factor XI deficiency 580
 - hemophilia carriers 580
 - platelet disorders 578–9
 - thrombocytopenia 579–80
 - von Willebrand disease 571–2, 574–8
 - warfarin 581
 - determination of 571
 - surgical treatment 581–2
 - considerations with coagulation defects 582–3
 - under-appreciation of coagulation defects 571–2
 - work up in coagulation defect patient 573–4
- menstruation disorders 570
 - hemostasis mechanism 571
 - see also* menorrhagia
- methionine synthesis pathway 285–6
- methylenetetrahydrofolate reductase (MTHFR) 285–6
 - C677T mutations 140, 286–7, 296–7
 - recurrent miscarriage association 60, 293, 353
- methylmalonic acid (MMA) 288
- miscarriage
 - homocysteine relationship 293
 - see also* recurrent miscarriage syndrome (RMS)
- misoprostol 391, 403
- modified B-Lynch suture 417

599 Index

molecular marker profiling, disseminated intravascular coagulation 34	ovarian hyperstimulation syndrome
monoclonal antibody specific immobilization of platelet antigens assay (MAIPA) 510	oxytocin
Montpellier Antiphospholipid (MAP) study 168	role in uterine contractions 390
multiple organ dysfunction syndrome (MODS) clinical manifestations 366	use as uterotonic agent 390–1, 403
with post partum hemorrhage 364, 425	
myocardial infarction, anticardiolipins and 158–9	packed red blood cells (PRBCs) 534–5
	indications 534–5
	post partum hemorrhage management 398–400
	preparation and storage 534
neonatal alloimmune thrombocytopenia (NAITP) 507–17	parturition
caused by human leukocyte antigens (HLA) 516–17	hemorrhage 362
anti-HLA antibodies 517	maternal physiology 371–2
diagnosis 517	parvovirus B19 infection 449–50, 452
caused by human platelet antigens (HPA) 507–12	Passovoy defect 385
clinical presentation 508–9	pentasaccharide 355
diagnosis 509–11	percutaneous umbilical blood sampling (PUBS) 476
HPA polymorphisms 507–8	thrombocytopenia assessment 493, 514
incidence 507	pictorial blood measurement chart (PBMC) 571
maternal history 509	placenta 250–2
pregnancy management in alloimmunized mother 511–12	fetal perfusion 251–2
prenatal screening 511	developmental lesions 258–9
prenatal therapeutic strategies 512	disturbances of fetal vascular integrity 258, 260–2
clinical presentation 512–13	obstructive lesions 258, 259–60
fetal management 513–15	maternal perfusion 250–1
fetal platelet count determination 513–14	developmental lesions 253–4
intrauterine platelet infusion (IUIPT) 514–15	disturbances of maternal vascular integrity 253, 255–7
intracranial hemorrhage (ICH) 513	obstructive lesions 253, 254–5
neonate management 515–16	sickle cell disease effects 445
transfusion therapy 515–16	thrombophilia and 259, 262–3
NESP (novel erythropoiesis-stimulating factor) 541	placental abruption 255–7, 389
neural tube defects (NTDs) 292–3	chronic abruption 256
folate deficiency relationship 292–3	disseminated intravascular coagulation and 13
vitamin B ₁₂ status and 293	marginal abruption 256
non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibition 82–3	plasma exchange (PE) therapy, thrombotic thrombocytopenic purpura 499
Novoseven (recombinant factor VIIa) 542	plasmin, in disseminated intravascular coagulation 19, 20–1
	assays 31–2
obesity, as risk factor for DVT 205–6	plasmin-alpha-2-plasmin inhibitor (PAP) complex assay 31–2
O’Leary stitch 414	plasminogen activator inhibitor type I (PAI-1) elevation 146
oral contraceptives, menorrhagia treatment with von Willebrand disease 577	plasminogen deficiency 145–6
Organon 564	platelet antigen genotyping 510–11
osteoporosis, heparin-associated 129–32, 350	paternal 511–12
ovarian cancer	platelet beta-thromboglobulin assay 32
venous thrombosis risks 310, 316	
during chemotherapy 324–5	
<i>see also</i> malignancy	

600 Index

- platelet count 80
 - disseminated intravascular coagulation 32
 - fetal 506
 - primary platelet disorders 91–2
- platelet defects 91–2, 389
 - antiplatelet medication effects 82–3
 - in recurrent miscarriage 55–8
 - menorrhagia and 578–9
 - diagnosis 579
 - prevalence 578–9
 - treatment 579
 - surgical considerations 583
 - see also* thrombocytopenia
- platelet factor 4 assay 32
- platelet function tests
 - in disseminated intravascular coagulation 32
 - platelet aggregation studies 81, 562
 - Platelet Function Analyzer-100 (PFA-100) 80–1
- platelet suspension immunofluorescence test (PSIFT) 509–10
- platelet transfusion 546
 - intrauterine transfusion (IUT) 514–15
 - neonatal alloimmune thrombocytopenia management 515–16
 - use of maternal platelets 516
- post partum hemorrhage management 401–2
- random donor platelets (RDPs) 535
- single donor platelets (SDPs) 535–7
- thrombocytopenia 495
- thrombotic thrombocytopenic purpura and 499
- post partum hemorrhage (PPH) 361–2
 - antepartum hemorrhage as predictor 365–6
 - blood component therapy 398–402
 - autotransfusion 400
 - cryoprecipitate 402
 - fresh frozen plasma 400–1
 - packed red blood cells 398–400
 - platelets 401–2
 - causes 369, 370
 - etiology determination 408
 - definitions 363, 364
 - diagnosis 392–3
 - disseminated intravascular coagulation 418–23
 - management 421–3
 - prevention 420–1
 - factor VII therapy 402
 - incidence 362–3
 - interventional radiology 408–10
 - massive (severe) PPH 363–5
 - monitoring 406–8
 - morbidity and mortality 362–3
 - pharmacologic therapy 403–6
 - antibiotics 405–6
 - antifibrinolytic agents 403–4
 - uterotonics 391, 403
 - vasopressors 404–5, 407
 - prenatal screening evaluation 372, 373
 - prevention 372–92
 - alpha-2-antiplasmin deficiency 385
 - antepartum hemorrhagic diatheses 373–7
 - antepartum preparation 372, 376
 - factor II defects 377–8
 - factor V defects 378–9
 - factor VII defects 379–80
 - factor VIII: C defects 380–2
 - factor IX defects 382–3
 - factor X deficiency 383–4
 - factor XI deficiency 384
 - factor XIII deficiency 385–6
 - fibrinogen defects 377
 - kininogen deficiency 385
 - labor management 389–92
 - Passovoy defect 385
 - platelet defects 389
 - prekallikrein deficiency 384
 - von Willebrand disease 386–8
 - resuscitation 396–8
 - risk factors 367, 369
 - surgical management 411–18
 - arterial ligation 414–15
 - hemostatic sutures 415–18
 - hysterectomy 418
 - tamponade 411–14
- postthrombotic syndrome 212
- preeclampsia 13–15, 495–6
 - acute atherosclerosis and 254
 - homocysteine and 294
 - thrombocytopenia association 495–6
 - with sickle cell disease 452
- pregnancy termination, with sickle cell disease 450
- preimplantation genetic diagnosis (PGD) 476–7
- prekallikrein deficiency 384
- prenatal diagnosis 469, 474–7
 - amniocentesis 475–6, 477
 - β thalassemia 460–1, 481
 - bleeding disorders 96
 - von Willebrand disease 485
 - chorionic villus sampling (CVS) 476, 477
 - Hb H disease 458–9
 - neonatal alloimmune thrombocytopenia 511

601 Index

- percutaneous umbilical blood sampling (PUBS) 476
- preimplantation genetic diagnosis (PGD) 476–7
- prerequisites 474–5
- Rh-D status 486
- sickle cell disease 449, 453, 481
- thrombocytopenia 493
- proconvertin deficiency 379–80
- progesterin releasing intrauterine device, menorrhagia treatment 581
- prostaglandins
 - role in uterine contractions 390
 - uterotonic use 403
 - side effects 403
- prosthetic heart valves
 - enoxaparin (Lovenox) safety issues in pregnancy 65–7, 127, 557
 - thrombosis prophylaxis during pregnancy 212, 353
- protein C 142
 - deficiency 142–4, 206–7
 - management 142–4
 - see also* activated protein C (APC)
- protein S 144
 - deficiency 144–5, 206–7
 - management 144–5
- prothrombin deficiency 377–8
- treatment 378
- prothrombin fragment 1.2 (PF 1+2) assay 29–30, 31
- prothrombin G20210A mutation 137–9, 207–8
 - management 138–9
 - recurrent miscarriage association 60
 - thrombosis risk 137–8
- prothrombin time (PT) 81
 - in disseminated intravascular coagulation 25–6
- pulmonary angiography
- pulmonary artery catheter 407
- pulmonary embolism (PE)
 - diagnosis 213–14
 - incidence in pregnancy 200
 - mortality 201
 - previous history as risk factor 204
 - risk in pregnancy 122
 - see also* thrombophilia in pregnancy; thrombosis; venous thromboembolism (VTE)
- pulmonary hyaline membranes 24–5
- pulse, post partum hemorrhage monitoring 406
- rabbit brain neutralization procedure 170
- radiotherapy, venous thrombosis risks 319–20
- recombinant factor VIIa (Novoseven) 542
- recurrent miscarriage syndrome (RMS) 55
 - blood coagulation protein/platelet defects and 55–8
 - hemorrhagic defects 55–6, 57, 63
 - procoagulant defects 58–61
 - thrombotic defects 56–7
 - causes 55, 56, 176
 - antiphospholipid antibody association 58–9, 64, 162–3, 208–9
- Dallas Thrombosis Hemostasis Clinical Center
 - experience 61–9
 - flow protocol 61
 - management 63–6
 - outcomes 67
 - patient characteristics 62–3
 - treatment review 68–9
 - management 63–6, 162–3, 351
 - guidelines 353–5
- red blood cell substitutes 541
- Refludan® 564–5
- reptilase time, disseminated intravascular coagulation 26
- resuscitation, post partum hemorrhage 396–8
- retained fetus syndrome, disseminated intravascular coagulation 13
- Rh immunoglobulin (RhIG) administration 111–12, 486
- Rh isoimmunization 108–10, 485–7
 - hemolytic disease of the fetus and newborn 107, 108–9
 - alloimmunized female management during pregnancy 112
 - clinical presentation 109–10
 - diagnosis 110
 - fetus management 112–13
 - partial D variant 109
 - prevention in Rh(D) negative, unsensitized female 111–12
 - protection by ABO-incompatibility 110
 - inheritance patterns 486
 - prenatal testing 486
- rituximab 499
- ruptured vasa previa 258
- Rusch catheter 413

602 Index

- schistocytes 24
- screening
 - anteartum hemorrhagic diatheses 372, 373
 - β thalassemia 460, 461, 462, 463
 - iron deficiency 281
- Sengstaken–Blakemore catheter 412–13
- septicemia, disseminated intravascular coagulation
 - and 17–18
 - management 37
- serotonin release assay (SRA) 562
- sickle cell disease 255, 444–54, 547–8
 - complications 450–3
 - acute anemic episodes 451–2
 - acute chest syndrome 450–1
 - CNS events 451
 - eclampsia 453
 - painful episode 451
 - preeclampsia 452
 - pregnancy-related complications 447
 - small for gestational age 452
 - contraception and 453
 - genetic counseling 453
 - inheritance patterns 481
 - placental circulation 445
 - pregnancy in 445–7
 - pregnancy management 445–450
 - antenatal care 447–8
 - blood transfusion 449–50, 547–8
 - delivery 450
 - laboratory testing 448–9
 - puerperium 450
 - supplements 449
 - termination 450
 - prenatal diagnosis 449, 453, 481
 - sickle erythrocyte characteristics 444–5
 - sickle hemoglobin 443
- sickle cell trait 453–4
- skin conditions
 - anticardiolipins and 159
 - heparin-related 132–3
- Sneddon’s syndrome 159, 160
- solid phase red cell assay (SPRCA) 510
- spina bifida 292
- splenectomy 494–5
- Sticky Platelet Syndrome (SPS) 147–8
 - management 148
- stroke
 - antiphospholipid antibodies and 160–1, 175–6
 - with sickle cell disease 451
- syncytial knots 254
- syntometrine 391
- systemic inflammatory response syndrome (SIRS) 418–19
- systemic lupus erythematosus 150
 - cardiac valvular disease and 159
 - see also* lupus anticoagulants (LA)
- tamoxifen therapy, venous thrombosis risk and 321, 326
- tamponade, post partum hemorrhage management 411–14
 - Foley catheter 412
 - large volume balloon 413–14
 - Rusch catheter 413
 - Sengstaken–Blakemore catheter 412–13
 - uterine packing 412
 - vaginal tamponade 412
- thalassemias 443
 - α thalassemia 455–6, 481–4
 - β thalassemia 459–61, 481
 - genetic counseling 460
 - heterozygotes 460
 - prenatal diagnosis 460–1, 481
 - screening 460, 461, 462, 463
 - Hb Bart’s hydrops fetalis 456–9, 483–4
 - fetal and maternal complications 457
 - gene deletions 457
 - genetic counseling 457–8
- thrombin
 - consequences of systemic activity 19–22
 - inhibitors, use in heparin-induced thrombocytopenia 564
 - Argatroban 565, 566
 - Bivalirudin 565
 - guidelines 566
 - hirudin 564–5, 566
 - see also* antithrombin (AT)
- thrombin time (TT) 82
 - in disseminated intravascular coagulation 26
- thrombocytopenia 83, 389, 490, 498
 - acute fatty liver of pregnancy (AFLP) 497
 - causes during pregnancy 491
 - differential diagnosis 561
 - fetal
 - assessment 493, 513–14
 - management 513–15
 - presentation 512–13
 - gestational (physiological) thrombocytopenia 490–1

603 Index

- hemolytic uremic syndrome (HUS) 499–500
- immune thrombocytopenic purpura (ITP) 492–5
 - menorrhagia and 579–80
 - neonatal 506
 - see also* immune thrombocytopenic purpura (ITP); neonatal alloimmune thrombocytopenia (NAITP)
 - pathological thrombocytopenia 491–5
 - preeclampsia/eclampsia association 495–6
 - thrombotic thrombocytopenic purpura (TTP) 497–9
 - see also* HELLP syndrome; heparin-induced thrombocytopenia (HIT)
- thrombogenesis 342
- thrombophilia in pregnancy 122–4, 134, 206–10, 344, 477–8
 - antiphospholipid syndromes 148–50, 208–9, 344
 - anticardiolipins 156–64, 208–9
 - classification 154, 164–6
 - lupus anticoagulants (LA) 150–6, 208–9
 - antithrombin (AT) deficiency 140–2, 206–7
 - antithrombotic therapy 122–3, 124–34
 - bridging therapy 126–7
 - heparin side effects 128–34
 - treatment monitoring 127
 - see also specific conditions*
 - dysfibrinogenemia 139, 377
 - factor V Cambridge mutation 136–7
 - factor V Hong Kong mutations 137
 - factor V HR2 haplotype 137
 - factor V Leiden mutation 134–6, 207–8
 - factor XII deficiency (Hageman trait) 139
 - fibrinolytic defects 145–6
 - genetic testing 478
 - heparin cofactor II (HC-II) deficiency 142
 - homocyst(e)inemia 139–40
 - inheritance 477–8
 - management guidelines 352
 - placental pathology 262–3
 - protein C deficiency 142–4, 206–7
 - protein S deficiency 144–5, 206–7
 - prothrombin G20210A mutation 137–9, 207–8
 - sticky platelet syndrome (SPS) 147–8
- thrombosis 134
 - anticardiolipins and 149, 156, 157–8, 160–1
 - fibrinolytic defects and 145–6
 - heparin-induced thrombocytopenia and 560–1
 - in disseminated intravascular coagulation 2, 20, 21, 22–3
 - management 37–8
 - morphological findings 23–5
 - significance 2, 21, 25
 - see also* disseminated intravascular coagulation
 - lupus anticoagulants and 149, 150–1
 - mortality 201
 - pathophysiology 341
 - placental 250, 259–60
 - intervillous thrombi 261
 - massive subchorial thrombosis 261
 - see also* placenta
 - pregnancy and 341–4
 - hemostatic changes in pregnancy 202, 342–3
 - incidence 200
 - thrombogenesis 342
 - thrombotic defects associated with recurrent miscarriage 56–7
 - procoagulant defects 58–9
 - see also* deep vein thrombosis (DVT); pulmonary embolism (PE); thrombophilia in pregnancy; venous thromboembolism
 - thrombotic thrombocytopenic purpura (TTP) 497–9
 - etiology 497–8
 - management 499
 - plasma exchange (PE) therapy 499
 - tissue plasminogen activator (tPA) deficiency 146
- TORCH viral infections 261
- tranexamic acid
 - disseminated intravascular coagulation therapy 40
- menorrhagia treatment
 - with factor XI deficiency 580
 - with von Willebrand disease 577–8
- post partum hemorrhage management 403–4
- transcatheter embolization, post partum hemorrhage management 408–10
- transferrin assay 279–80
- transfusion-transmitted diseases (TTD) 529–30
- trophotropism 258
- umbilical cord 258
 - aberrant membranous vessel 258
 - controlled cord traction 391–2
 - furcate cord 258
 - hemangiomas 258–9
 - marginal or membranous insertion 258
- umbilical vessels
 - sickle cell disease and 445
 - traumatic tears 261

604 Index

- uremic bleeding 91
 - management 539–40
- urinary output, post partum hemorrhage
 - monitoring 406
- uterine artery ligation 414
- uterine cancer
 - venous thrombosis risks 310, 316
 - see also* malignancy
- uterine contractions 390
 - post partum hemorrhage management 403
 - prevention 390–1, 392
- uterine massage 392
- uterine packing 412
- uterotonic agents 390–1, 403
- vaginal tamponade 412
- vascular coils 409
- vasopressors, post partum hemorrhage
 - management 404–5
 - monitoring 407
- venous thromboembolism (VTE)
 - management guidelines in pregnancy 352
 - at risk patients 352
 - patients already receiving
 - anticoagulation 353
 - patients at risk for pregnancy loss 353–5
 - patients with mechanical heart valves 353
 - prophylaxis in cancer patients 310–11
 - during chemotherapy 326–7, 332–3
 - during radiotherapy 320
 - during surgery 315–19, 331–2
 - recommendations 331–3
 - with central venous catheters 328–31, 333
 - risk factors 311–14
 - risk-assessed model (RAM) 311, 312
 - risk in malignancy 310, 311
 - age and 312–13, 314–19
 - during cancer surgery 313, 314, 315–19
 - during chemotherapy 320–7, 324–5
 - during radiotherapy 319–20
 - influencing factors 311–14
 - with central venous catheters 327–31
 - see also* deep vein thrombosis (DVT); pulmonary embolism (PE); thrombosis
- ventilation-perfusion scan
- viral infection, disseminated intravascular coagulation and 18
- vitamin B₁₂ 284–5
 - deficiency
 - diagnosis 287–9
 - hematological sequelae 290–1
 - neural tube defects and 293
 - neuropsychiatric symptoms 291
 - treatment 295–6
 - homocysteine interrelationship 285–6
 - requirements in pregnancy 290
- von Willebrand disease (VWD) 83–91, 386–8, 574–8
 - acquired von Willebrand syndrome (aVWS) 87
 - classification 84–7, 387, 484–5
 - Type 1 84–5
 - Type 2A 85
 - Type 2B 86
 - Type 2M 86
 - Type 2N 86–7
 - Type 3 87
 - diagnosis 86, 87–8, 387, 485, 576
 - prenatal diagnosis 485
 - factor VIII: C deficiency comparison 388
 - inheritance patterns 484–5
 - management
 - during pregnancy 88–91, 386–8, 539
 - with menorrhagia 576–8
 - menorrhagia and 571–2, 574–8
 - treatment 576–8
 - prevalence 574–6
 - surgical considerations 582–3
- von Willebrand factor (VWF) 83–4
 - in thrombotic thrombocytopenic purpura 497–8
 - replacement therapy 88–9, 90–1
 - stimulant therapy 89–90
- warfarin treatment
 - factor V Cambridge mutation 137
 - factor V Leiden mutation 135
 - lupus anticoagulant thrombosis syndrome 155
 - menorrhagia and 581
 - protein C deficiency 143
 - protein S deficiency 144
 - reversal of warfarin effect 537–8
 - venous thrombosis prophylaxis
 - during chemotherapy 326–7
 - with central venous catheters 328–31, 333
- X-linked inheritance 473
- ximelagatran 355